Ye Qifa, Zeng Cheng, Wang Yanfeng, Ming Yingzi, Wan Qiquan, Ye Shaojun, Xiong Yan, Li Ling
Wuhan University, Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan, Hubei, China (mainland).
The 3rd Xiangya Hospital of Central South University, Research Center of National Health Ministry on Transplantation Medicine Engineering and Technology, Changsha, Hunan, China (mainland).
Ann Transplant. 2018 Jan 30;23:81-88. doi: 10.12659/aot.905983.
BACKGROUND Ante-situm resection and auto-transplantation (ante-situm for short) provides a more aggressive approach to conventionally unresectable hepatocellular carcinoma (HCC). We described the long-term outcomes of patients with HCCs who underwent this technique. MATERIAL AND METHODS Between October 2005 and December 2016, we performed 23 ante-situm liver resections. We evaluated postoperative complications, 90-day mortality, recurrence, and long-term survival rates, and reviewed the literature on this topic. RESULTS Five types of complications associated with six patients were observed.: 1) primary nonfunctioning liver, thus receiving a liver transplantation; 2) initial poor liver function with recovery two weeks after treatment; 3) diagnoses of portal vein tumor thrombosis, biliary fistula, and small-for-size syndrome, respectively. The median follow-up was 3.6 years; 12 out of 23 patients were alive at the end of the study. One patient who had hepatic recurrence was lost to follow-up after three months. One patient died of multiple organ dysfunction syndrome after the operation, nine patients died due to hepatic recurrence and/or extrahepatic metastasis of HCC. The one-year, three-year, five-year, and 10-year survival rates were 65.2%, 56.5%, 50.9%, and 20.3%, respectively. The one-year, three-year, five-year, and 10-year recurrence rates were 60.9%, 50.7%, 50.7%, and 50.7%, respectively. The chi-square test revealed the patients with recurrence after ante-situm technique were more likely to have poor prognosis (mortality of patients with recurrence versus no-recurrence: 88.9% versus 14.3%, p<0.05) and a strong association was evidenced by Cramer's V statistic (Cramer's V=0.734). CONCLUSIONS Ante-situm procedure showed benefits in select patients with HCCs who had contraindications for conventional resection operations. In our case series, the ante-situm technique resulted in lower mortality compared to other ex-vivo hepatic resection techniques reported in the literature and similar long-term efficacy compared to cases of HCCs suitable for conventional resections. HCCs recurrence was a major risk factor associated with the survival rate of ante-situm technique.
背景 原位前切除及自体移植术(简称原位前术)为传统上无法切除的肝细胞癌(HCC)提供了一种更积极的治疗方法。我们描述了接受该技术的HCC患者的长期预后情况。材料与方法 2005年10月至2016年12月期间,我们实施了23例原位前肝切除术。我们评估了术后并发症、90天死亡率、复发率及长期生存率,并回顾了关于该主题的文献。结果 观察到6例患者出现5种类型的并发症:1)原发性肝功能无功能,因此接受了肝移植;2)初始肝功能差,治疗两周后恢复;3)分别诊断为门静脉肿瘤血栓形成、胆瘘和小肝综合征。中位随访时间为3.6年;研究结束时,23例患者中有12例存活。1例肝复发患者在3个月后失访。1例患者术后死于多器官功能障碍综合征,9例患者死于HCC肝复发和/或肝外转移。1年、3年、5年和10年生存率分别为65.2%、56.5%、50.9%和20.3%。1年、3年、5年和10年复发率分别为60.9%、50.7%、50.7%和50.7%。卡方检验显示,原位前技术术后复发的患者预后更差(复发患者与未复发患者的死亡率:88.9%对14.3%,p<0.05),克莱默V统计量证明存在强关联(克莱默V=0.734)。结论 原位前手术对有传统切除手术禁忌证的特定HCC患者显示出益处。在我们的病例系列中,与文献报道的其他离体肝切除技术相比,原位前技术导致的死亡率更低,与适合传统切除的HCC病例相比,长期疗效相似。HCC复发是与原位前技术生存率相关的主要危险因素。